Riboxin 0.2 g tablets # 50

Author Ольга Кияница


Amount in a package 50
Product form Pills
Manufacturer Kiev vitamin plant PAT (Ukraine, Kiev)
Registration certificate UA/0416/01/01
The main medicament Riboxin
morion code 38061



Active ingredient : 1 tablet contains inosine (in terms of 100% dry matter) - 200 mg;

auxiliary substances: potato starch, corn starch, sucrose, stearic acid or calcium stearate, film coating mixture Opadry II Yellow (aluminum lacquers (indigotine (E 132), yellow sunset FCF (E 110), hydroxypropylmethyl cellulose, lactose monohydrate, polyethylene glycol , quinoline yellow (E 104), titanium dioxide (E 171), triacetin)).

Dosage form. Film-coated tablets.

Pharmacotherapeutic group. Cardiological preparations. The code of automatic telephone exchange С01Е В14 **.

Clinical characteristics.

Indications. Riboxin ® is prescribed in complex therapy for:

  • ischemic heart disease (including in the post-infarction period);
  • heart rhythm disorders caused by the use of cardiac glycosides;
  • dystrophic changes in the myocardium;
  • with liver diseases (hepatitis, cirrhosis of various etiologies).

Contraindications. Hypersensitivity to inosine, gout, hyperuricemia, periods of pregnancy and lactation.

Method of administration and dose. Riboxin® is administered to adults inside, before meals. The initial daily intake for adults is 3-4 tablets (600-800 mg), at the rate of 1 tablet (200 mg) 3-4 times a day. With good tolerability of the drug, the dose is increased for 2-3 days from 6 (1.2 g) to 12 tablets (2.4 g) per day, at the rate of 2-4 tablets (400-800 mg) 3-4 times a day . The duration of the course of therapy is from 4 weeks to 3 months.

Adverse reactions. Possible itching, skin hyperemia; in isolated cases, the level of urea in the blood can increase. With prolonged use in large doses, an exacerbation of gout is possible.

Overdose. Allergic reactions, manifested by itching, flushing of the skin; digestive disorders in the form of nausea, abdominal pain, diarrhea.

Treatment: it is necessary to cancel the drug, prescribe symptomatic therapy.

Use during pregnancy or lactation. Clinical studies on the use of the drug during pregnancy and lactation are not available, so during pregnancy or breast-feeding the drug is contraindicated.

Children. Clinical studies on the use of the drug in children are absent.

Features of application. With prolonged intake of the drug, it is necessary to monitor the concentration of uric acid in the blood.

In case of renal insufficiency, the drug can be used only when, in the opinion of the doctor, the expected positive effect will exceed the risk of application.

The ability to influence the speed of reactions when driving or working with other machinery. Data on the effect of the drug on the ability to drive a car or work with complex mechanisms, no.

Interaction with other drugs and other types of interactions.

Reduces toxicity and prevents the development of arrhythmia when used with cardiac glycosides (digitoxin, digoxin), it can be combined with other anabolic drugs (potassium orotate, methandrostenolone). With simultaneous use with β-adrenoblockers, the effect of Riboxin ® does not change. Riboxin ® enhances the effects of heparin, increases the duration of its action. The drug is incompatible with alkaloids. When interacting with them, the alkaloid base is released and insoluble compounds are formed. With tannin forms a precipitate. Incompatible with acids and alcohols, salts of heavy metals. Incompatible with vitamin B 6 (pyridoxine hydrochloride), there is an inactivation of both compounds.

Pharmacological properties.

Pharmacodynamics. Inosine, the purine nucleoside, is a precursor of adenosine triphosphate (ATP).

Inosin accelerates the dissociation of oxygen from oxyhemoglobin, which improves the supply of oxygen to the tissues, improves coronary circulation and myocardial metabolism. Increases the energy balance of the myocardium.

Normalizes the function of the liver by improving the energy processes in the hepatocytes.

Increases the activity of a number of enzymes in the Krebs cycle. Inosine stimulates the synthesis of nucleotides, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract).

The drug has antihypoxic, antiarrhythmic, anabolic action.

Pharmacokinetics. It is well adsorbed in the small intestine. Metabolised in the liver, including in the energy and plastic metabolism. Excreted mainly in the urine, slightly - with feces and bile.

Pharmaceutical characteristics.

Basic physical and chemical properties: tablets covered with a film membrane, yellow, with biconvex surface.

Shelf life. 3 years.

Storage conditions. Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Packaging. 10 tablets in a blister pack.

10 tablets in a blister; 5 blisters per pack.

Category of vacation. On prescription.

0.00 avg. rating (0% score) - 0 votes - votes